Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2020-09-28 Declaration of Voting R…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Result of General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Result of General Meeting' and provides a detailed table of voting results for five specific resolutions, including 'Votes For', 'Votes Against', and 'Total Votes Cast'. This directly matches the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2020-09-28 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Mereo Biopharma Group PLC, for the month of September 2020. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1337 characters), and it primarily serves as a report submission rather than a full financial or management report. According to the rules, Form 6-K filings are regulatory filings for foreign issuers and typically fall under the Regulatory Filings (RNS) category unless they contain detailed financial data or specific report types. Therefore, this document is best classified as Regulatory Filings (RNS).
2020-09-28 English
Changes to Board of Directors
Board/Management Information Classification · 100% confidence The document is an official announcement from Mereo BioPharma Group plc regarding the appointment of two new members to its Board of Directors and the departure of an existing director. It explicitly states 'Mereo BioPharma Announces Changes to Board of Directors' in the headline. This content falls directly under the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-09-28 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit and is signed by the General Counsel. The document length is short (1337 characters) and it primarily serves as a regulatory filing to report current information rather than a full financial report or detailed presentation. There is no substantive financial data or detailed report content, only a notification and a press release reference. Therefore, it fits best under Regulatory Filings (RNS).
2020-09-24 English
FDA Rare Pediatric Disease Designation
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the Regulatory News Service (RNS) of the London Stock Exchange. It announces that Mereo BioPharma has received FDA Rare Pediatric Disease designation for its drug candidate, setrusumab. This is a corporate announcement regarding regulatory developments and business operations, which does not fit into specific categories like financial reports, dividends, or board changes. Therefore, it is classified as a general regulatory filing.
2020-09-24 English
Notice of Interim Results
Report Publication Announcement Classification · 100% confidence The document is an announcement from Mereo BioPharma stating that they will release their interim financial results on a future date (September 29, 2020) and will host a conference call. It does not contain the actual financial results, but rather serves as a notification of the upcoming report and call. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2020-09-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.